NYSE:CTLT
Catalent Inc Stock News
$55.98
-0.220 (-0.391%)
At Close: May 09, 2024
Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday
12:32pm, Monday, 10'th Apr 2023 Benzinga
Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
03:00pm, Tuesday, 04'th Apr 2023 Benzinga
Upgrades
Raymond James upgraded the previous rating for Extra Space Storage Inc (NYSE:EXR) from Outperform to Strong Buy. Extra Space Storage earned $2.09 in the fourth quarter, compared to $1.91 in t
Where Catalent Stands With Analysts
07:00pm, Monday, 03'rd Apr 2023 Benzinga
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
2
0
0
Last 30D
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
03:00pm, Monday, 03'rd Apr 2023 Benzinga
Upgrades
For Macy's Inc (NYSE:M), JP Morgan upgraded the previous rating of Neutral to Overweight. In the fourth quarter, Macy's showed an EPS of $1.88, compared to $2.45 from the year-ago quarter. At
Three Stocks Turn $10,000 To $25,265 In Just 3 Months
07:30am, Friday, 31'st Mar 2023
Investors enjoyed a small S&P 500 rally in March. But there were much more lucrative places to put money in the month.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
04:34pm, Thursday, 30'th Mar 2023 Zacks Investment Research
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
01:42pm, Thursday, 30'th Mar 2023
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
11:20am, Saturday, 25'th Mar 2023 The Motley Fool
These companies strive to bring down the cost of developing new therapies.
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses
03:16pm, Friday, 24'th Mar 2023 Zacks Investment Research
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses
01:00pm, Friday, 24'th Mar 2023
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
03:13pm, Monday, 20'th Mar 2023 Zacks Investment Research
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
12:14pm, Monday, 20'th Mar 2023
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
Catalent: Ready For Growth Despite A Tough Year, Falling Revenues And A Lawsuit
09:28am, Monday, 20'th Mar 2023
Catalent's COVID-19 related revenues have fallen, but cushioned by growth in other areas and they continue to expand their activities. A lawsuit over accusations of misleading investors is ongoing tha
Stock market volatility this week has triggered a new sell signal
10:12pm, Thursday, 16'th Mar 2023 MarketWatch
Stay cautious until new highs outnumber new lows on the NYSE.
Zoetis (ZTS) Down 6.5% Since Last Earnings Report: Can It Rebound?
03:30pm, Thursday, 16'th Mar 2023 Zacks Investment Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
